Curon Biopharma

Curon Biopharma is a clinical-stage biotechnology company based in Shanghai, China, focused on the discovery and development of next-generation therapeutic antibodies for oncology and inflammatory diseases. The company utilizes its proprietary Mab-Engine platform to engineer highly differentiated multi-specific antibodies and targeted biologics. In August 2024, Curon reached a significant milestone by selling its lead asset, CN201 (a CD3xCD19 bispecific antibody), to Merck (MSD) for $700 million upfront. The company continues to advance a diverse pipeline of internal programs, including bispecifics targeting BCMA and monoclonal antibodies targeting the SIRPα/CD47 pathway and Claudin 18.2. Curon is supported by a strong syndicate of investors, including 6 Dimensions Capital and Temasek.